Published in Blood Weekly, July 13th, 2006 MiRNAs are a recently
discovered class of natural antisense RNAs that are important in
the regulation of cellular functions. These data demonstrate
that antisense inhibition is a powerful technique to regulate
the function of miRNAs and suggest that miR-122 may be an
attractive therapeutic target for cardiovascular and metabolic
diseases. Want to see the full article? Welcome to NewsRx! Learn
more about a six-week, no-risk free trial of Blood Weekly NewsRx
also is available at LexisNexis, Gale, ProQuest, Factiva,
Dialog, Thomson Reuters, NewsEdge, and Dow Jones.